CUSIP: 81362J100
Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
8,776,186
-
Share change
-
+6,199,287
-
Total reported value
-
$10,616,351
-
Put/Call ratio
-
450%
-
Price per share
-
$1.21
-
Number of holders
-
53
-
Value change
-
+$7,402,934
-
Number of buys
-
33
-
Number of sells
-
14
Quarterly Holders Quick Answers
What is CUSIP 81362J100?
CUSIP 81362J100 identifies EYES - SECOND SIGHT MED PRODS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2017
-
Previous quarter:
Q4 2016
Recent filing periods for CUSIP 81362J100:
Institutional Holders of SECOND SIGHT MED PRODS INC - COM (EYES) as of Q1 2017
As of 31 Mar 2017,
SECOND SIGHT MED PRODS INC - COM (EYES) was held by
53 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,776,186 shares.
The largest 10 holders included
Versant Venture Management, LLC, BlackRock Inc., VANGUARD GROUP INC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, VAN DEN BERG MANAGEMENT I, INC, Anson Funds Management LP, STATE STREET CORP, Psagot Investment House Ltd., NORTHERN TRUST CORP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
53
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.